333 related articles for article (PubMed ID: 28072858)
1. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis.
Hu Q; Sun TT; Hong J; Fang JY; Xiong H; Meltzer SJ
PLoS One; 2017; 12(1):e0169691. PubMed ID: 28072858
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
Yao H; Wang L; Li H; Xu S; Bai Z; Wu Y; Chen H; Goyal H; Qi X
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):79-88. PubMed ID: 34806503
[TBL] [Abstract][Full Text] [Related]
3. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Chen Y; Sun C; Wu Y; Chen X; Kailas S; Karadsheh Z; Li G; Guo Z; Yang H; Hu L; Zhou Q
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2681-2691. PubMed ID: 33575855
[TBL] [Abstract][Full Text] [Related]
4. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
5. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
6. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
7. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.
Singh S; Garg SK; Singh PP; Iyer PG; El-Serag HB
Gut; 2014 Aug; 63(8):1229-37. PubMed ID: 24221456
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
9. Risk of esophageal adenocarcinoma in patients with Barrett's esophagus using proton pump inhibitors: a systematic review with meta-analysis and sequential trial analysis.
Li L; Cao Z; Zhang C; Pan W
Transl Cancer Res; 2021 Apr; 10(4):1620-1627. PubMed ID: 35116488
[TBL] [Abstract][Full Text] [Related]
10. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
11. Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.
Loomans-Kropp HA; Chaloux M; Richmond E; Umar A
Cancer Prev Res (Phila); 2021 Feb; 14(2):195-204. PubMed ID: 32998939
[TBL] [Abstract][Full Text] [Related]
12. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis.
Krishnamoorthi R; Mohan BP; Jayaraj M; Wang KK; Katzka DA; Ross A; Adler DG; Iyer PG
Gastrointest Endosc; 2020 Jan; 91(1):3-10.e3. PubMed ID: 31421077
[TBL] [Abstract][Full Text] [Related]
13. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR
J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977
[TBL] [Abstract][Full Text] [Related]
14. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
16. Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus.
Shah SL; Dunbar K
Curr Gastroenterol Rep; 2023 Dec; 25(12):374-379. PubMed ID: 37940812
[TBL] [Abstract][Full Text] [Related]
17. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
19. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.
Singh S; Manickam P; Amin AV; Samala N; Schouten LJ; Iyer PG; Desai TK
Gastrointest Endosc; 2014 Jun; 79(6):897-909.e4; quiz 983.e1, 983.e3. PubMed ID: 24556051
[TBL] [Abstract][Full Text] [Related]
20. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]